The Bothell-based Biotechnology Company; Seattle Genetics is focused on innovative empowered monoclonal antibody-based therapies to aid in the treatment of cancer. The company is a global leader in the development of antibody-drug conjugates (ADCs), an innovation that assists in harnessing the targeting capability of antibodies to direct cell-killing agents to cancer cells. ADCs are designed to single out non-targeting cells, thereby reducing the adverse toxic effects of traditional chemotherapy. This procedure has the potential to improve antitumor activity.
ADCETRIS (Brentuximab Vedotin), which is the company’s main product, is commercially available in over 60 nations including European Union, Canada, U.S., and Japan. The availability of ADCETRIS in these countries has been made possible with the collaboration between Seattle Genetics and Takeda Pharmaceutical Company Limited. Seattle Genetics has exclusive rights to market Brentuximab vedotin in the United States and Canada while Takeda Pharmaceutical has the rights to market the product in the remaining nations.
The CD30-targeted ADC is being tested broadly in many ongoing clinical trials. These trials will serve as a basis to evaluate the product’s therapeutic potential. Apart from Brentuximab vedotin, Seattle Genetics is also working to improve vadastuximab Talirine (SGN-CD33A; 33A). Vadastuximab Talirine is expected to proceed to the third phase for acute myeloid leukemia later this year. The company is also working on a broad pipeline of products, including Enfortumab Vedotin, SEA-CD40, SGN-CD19B, SGN-CD70A,(Denintuzumab Mafodotin), SGN-CD19A; 19A, ASG-15ME, ASG-22ME, and SGN-LIV1A.
These products are a result of collaborations between Seattle Genetics and different biotechnology companies including GlaxoSmithKline, AbbVie, Bayer, Pfizer and Genentech
The President of Seattle Genetics: Clay B. Siegall
Clay B. Siegall is the co-founder of Seattle Genetics. He founded the company in 1998. Currently, he is serving as the company’s Chief Executive Officer, President, as well as Chairman of the Board. The company was established on a foundation of detailed research, scientific innovation, drug development practices and of course a passion for assisting cancer patients.
Mr. Siegall has steered the company to its present position. It is under his leadership that the company’s first ADC product, ADCETRIS (Brentuximab Vedotin) was approved. Brentuximab Vedotin is now a global brand being commercialized in over 60 nations. It is also during his tenure that the company has entered into different strategic licenses for its ADC innovation. Mr. Siegall is also a renowned author who has over 70 publications. On top of that, he holds over 10 patents.